Main Menu
Main Menu
Menu

Antibody Protein Sequencing (2017)

by

Overview

Rapid Novor, is a Kitchener-Waterloo based biotech company that provides rapid, accurate, de novo protein sequencing services across Canada and internationally. Rapid Novor currently offers monoclonal antibody protein sequencing to biopharmaceutical companies and academic labs where antibody development is key to their research, e.g. immunotherapy development. Rapid Novor will utilize the investment from Ontario Genomics to support expansion of this proteomic and bioinformatics-based technology to enable sequencing of polyclonal antibody proteins. Development of this novel antibody sequencing platform will address an unmet need for many R&D groups, allowing the company to increase its competitiveness and grow its revenue.

Biotechnology-Based Production of Natural Leaf-aldehyde (2017)

by

Overview

Ardra is a specialty chemicals company focused on the production of natural ingredients for the cosmetics and flavour and fragrance industries. Their synthetic biology platform uses designer biochemical pathways to produce a large portfolio of high-value products. The cosmetics and flavour and fragrances industries are dominated by petrochemical-derived ingredients, as natural ingredients have fluctuating and high prices along with seasonal variations. Ardra’s processes use renewable feedstock such as agricultural or forestry biomass, and engineered microbes to allow for low cost production and a steady supply of natural ingredients at a constant price. The investment from Ontario Genomics will advance the development of natural leaf aldehyde, a green leaf volatile used in green apple flavour, and as a scent in perfumery.

Avoiding drug-resistant fungal infections (2018)

by

Overview

Toronto start-up Bright Angel Therapeutics is developing novel treatments for fungal diseases, a global public health problem. Data compiled by the Global Action Fund for Fungal Infections (GAFFI) show that “over 300 million people are afflicted with a serious fungal infection and 25 million are at high risk of dying or losing their sight.”  Mortality due to fungal infections is primarily due to the development of resistance to the few available anti-fungal compounds. Ontario Genomics’ investment will help Bright Angel Therapeutics develop new compounds that exploit a novel strategy to treat fungal infections. By targeting a stress response mechanism that enables fungi to become drug-resistant, this strategy will transform existing antifungals from ineffective to highly efficacious against all the leading fungal pathogens, enabling the company to tap into the existing very large antifungal market.